XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Segment Information (Tables)
3 Months Ended
Jun. 30, 2021
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
  

Three Months Ended June 30,

 
  

2021

  

2020

 

Total revenues (a)

        

Sterilization and Disinfection Control

 $15,150  $13,067 

Biopharmaceutical Development

  8,877   5,949 

Instruments

  7,562   7,680 

Continuous Monitoring

  3,331   3,245 

Total revenues (a)

 $34,920  $29,941 
         

Gross profit (loss)

        

Sterilization and Disinfection Control

 $11,428  $10,021 

Biopharmaceutical Development

  4,692   4,466 

Instruments

  4,660   4,688 

Continuous Monitoring

  1,452   1,185 

Reportable segment gross profit

  22,232   20,360 

Corporate and Other (b)

  (21)  (20)

Gross profit

 $22,211  $20,340 

Reconciling Items:

        

Operating expenses

  19,088   16,770 

Operating income

  3,123   3,570 

Nonoperating expense, net

  1,705   2,816 

Earnings before income taxes

 $1,418  $754 
Reconciliation of Assets from Segment to Consolidated [Table Text Block]
  

June 30,

  

March 31,

 
  

2021

  

2021

 

Sterilization and Disinfection Control

 $2,254  $2,333 

Biopharmaceutical Development

  4,907   4,162 

Instruments

  3,304   3,253 

Continuous Monitoring

  1,657   1,430 

Total inventories

 $12,122  $11,178